KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Jazz Pharmaceuticals (JAZZ) Non-Current Deffered Revenue (2016 - 2022)

Jazz Pharmaceuticals has reported Non-Current Deffered Revenue over the past 13 years, most recently at $116000.0 for Q3 2022.

  • Quarterly results put Non-Current Deffered Revenue at $116000.0 for Q3 2022, down 88.24% from a year ago — trailing twelve months through Sep 2022 was $116000.0 (down 88.24% YoY), and the annual figure for FY2021 was $463000.0, down 80.0%.
  • Non-Current Deffered Revenue for Q3 2022 was $116000.0 at Jazz Pharmaceuticals, down from $231000.0 in the prior quarter.
  • Over the last five years, Non-Current Deffered Revenue for JAZZ hit a ceiling of $13.6 million in Q1 2018 and a floor of $116000.0 in Q3 2022.
  • Median Non-Current Deffered Revenue over the past 5 years was $3.6 million (2020), compared with a mean of $4.8 million.
  • Biggest five-year swings in Non-Current Deffered Revenue: tumbled 38.41% in 2019 and later plummeted 88.24% in 2022.
  • Jazz Pharmaceuticals' Non-Current Deffered Revenue stood at $9.6 million in 2018, then tumbled by 49.26% to $4.9 million in 2019, then plummeted by 52.38% to $2.3 million in 2020, then crashed by 80.0% to $463000.0 in 2021, then crashed by 74.95% to $116000.0 in 2022.
  • The last three reported values for Non-Current Deffered Revenue were $116000.0 (Q3 2022), $231000.0 (Q2 2022), and $347000.0 (Q1 2022) per Business Quant data.